Jake Scott

🚨 New in @JClinInvest 🚨 HPV+ oropharynx patients do not all benefit equally from the same radiation dose. Our study shows that genomics (via GARD) can guide personalized RT de-escalation—safely sparing toxicity without losing cure. Paper 👉 doi.org/10.1172/JCI194… #ASTRO25

The primary is the source of first progression in >50% of cases of #lungcancer patients, and TRACERx showed us that in 32% of NSCLC the primary polyclonally seeds metastases. In our @IASLC consensus, now in JTO shorturl.at/GzAe2, makes the case for eradicating it with #radiotherapy. The EGFRm phase III data are the most compelling OS 34.4 vs 26.2 months with TKI+RT. There are still unresolved questions in the non-AGA population. We are opening the phase III PRIME-LUNG trial shorturl.at/26apO @TROGfightcancer @TOGAANZ to answer this question! #radonc

Peak snapping turtle nesting season!! Saw three this morning on my ride including these two right next to one another (and next to the bike path). Don’t disturb! @clevemetroparks

"The greatest shortcoming of the human race,” he said, “is our inability to understand the exponential function" (c) Albert Bartlett Why You Didn’t See It Coming nautil.us/issue/29/scali… via @NautilusMag

Excellent article @NimaSharifiMD an outstanding clinician scientist- my friend and collaborator @NEJM how fasting or a fasting mimicking diet can augment the effects of hormonal therapy in breast cancer @OncoAlert @theNCI

✨ Inspiring to see @imrtlee representing ☢️ radiation oncology on the ASCO main stage. Practice changing work reducing treatment toxicities and integrating radiographic biomarkers to personalize radiation @MSK_RadOnc @MSKCancerCenter #ASCO26 #RadOnc

🧬 Can tumor genomics be used to personalize radiation dose? Grateful to present results from our phase II trial on dose de-escalated radiation therapy for ATM altered tumors at #ASCO2026 Great to see ☢️ #Radiation in the early-phase #PrecisionOncology space!

Our "evolutionary antifragile therapy" paper is now posted online (Cancer Research): aacrjournals.org/cancerres/arti… First experimental validation of antifragility in cancer (ALK inhibitors in lung)! An awesome collaboration involving @ara_anderson, @AndriyMarusyk, @Binadesai14 et al

Re-irradiation planning is now in RadRisk v2.0 🧵 Enter two RT courses (or upload DVHs), pick your OAR, and get cumulative BED + EQD₂ with time-discounted repair via the ReTEC model (Grimm 2026). radrisk.app #RadOnc #Reirradiation #SBRT #MedPhys #RadiationOncology

Our comment on recent excellent @NatureGenet paper from @naxerova Age identifies cancer drivers hidden within the genome nature.com/articles/s4158…

The figure below is my attempt to tell that story. We’re still learning how best to use this information. But the core idea is no longer theoretical: tumor genomics can help quantify the biological effect of radiation and bring that information into real treatment decisions. 8/n

Scientific American recently featured research from CWRU Physics' COMPACT collaboration, led by Professor Glenn Starkman, exploring alternative cosmic topologies and challenging the assumption that our universe is flat and infinite. Read more: scientificamerican.com/article/we-tho… #CWRU

🚨⭐️HOT off the press 👉Our Editorial in @NatRevDrugDisc Nature Reviews Drug Discovery is out TODAY, publishing simultaneously with @ASCO #ASCO26 meeting! 🎉 👉"Closing the Paediatric gap in cancer drug development: a call to industry" 👉Delighted to publish this with my amazing friend & co-author @CuglievanBranko @UTMDAnderson 👉This piece is close to my heart 👉 A call to action on closing the pediatric oncology drug development gap. 👉Children with cancer deserve the SAME urgency, the SAME rigor, and the SAME speed as adults @NaturePortfolio 👉Please share this because this message widely as needs to be heard. 👉And a very special thank you to the brilliant Editor-in-Chief, Dr. Peter Kirkpatrick, who published this with newspaper speed. That is why Nature Reviews Drug Discovery has an impact factor > 100+ 🙏 👉To every patient & family who has waited too long this one's for you @OncoAlert @oncodaily @OpenMedicineHQ Link: nature.com/articles/d4157…

@baym Also it seems like putting bugs INTO the place where the compute is happening is antithetical to good coding practice. What would Emily Noether say?! #WWENS

Bioproducts are the future

Congratulations to Christina Chukri and Ryan Kolonick - our two young researchers @ClevelandClinic for presenting @ASCO #asco26 Implementation of a CRC led clinical trial model in early phase trials

If you like thinking about what math can do for biology and vice versa, you might like this public talk I gave a year ago. It contains a lot of stories from my own life. "From Math to Bio and Back: Reflections on a Two Way Street" youtu.be/feLiP5-lkV0?si…

At AACR last month, I received many questions about grant applications. Today on @theNCI Bottom Line blog, I’m providing straight answers on where things stand, and what we’re doing to fund the best science as swiftly as possible: go.nih.gov/CXfBQV1

And then there were 6 Gold Medals for UCLA Radiation Oncology! 1) Dan Low 🥇 2) David Beyer 🥇 3) Michael Steinberg 🥇 4) Bill McBride 🥇 5) Rodney Withers 🥇 6) Robert Parker 🥇 #MyLifeWithDanLow

It should be noted that the @dtbergman - a rising PGY-3 at MSKCC #RadOnc led this work. The future is bright!!

Privilege to work with Jake (@CancerConnector) et al. to make sure we carefully translate RSI into the clinical NGS era to enable biologically-informed radiotherapy. Please get in touch to team up for clinical validation and to join the GARD Working Group!

See also a more detailed discussion on LinkedIn. End 🧵 9/9 linkedin.com/posts/jacob-sc…

Did you know that nearly half of all cancer cures involve #RadiationTherapy? and yet we're largely left out of #PrecisionMedicine discussions. 🧵 1/n: new preprint opening the door for precision radiation oncology adoption through RNAseq-based #GARD biorxiv.org/content/10.648…